​

GSK (GSK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GSK Stock Forecast

GSK stock forecast is as follows: an average price target of $53.00 (represents a 57.74% upside from GSK’s last price of $33.60) and a rating consensus of 'Hold', based on 11 wall street analysts offering a 1-year stock forecast.

GSK Price Target

The average price target for GSK (GSK) is $53.00 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $53.00 to $53.00. This represents a potential 57.74% upside from GSK's last price of $33.60.

GSK Analyst Ratings

Hold

According to 11 Wall Street analysts, GSK's rating consensus is 'Hold'. The analyst rating breakdown for GSK stock is 0 'Strong Buy' (0.00%), 3 'Buy' (27.27%), 8 'Hold' (72.73%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

GSK Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 02, 2024Peter WelfordJefferies$53.00$38.3838.09%57.74%
Apr 11, 2024Vamil DivanGuggenheim$36.00$40.69-11.53%7.14%
Apr 11, 2024Mark PurcellMorgan Stanley$85.00$40.69108.90%152.98%

The latest GSK stock forecast, released on Jul 02, 2024 by Peter Welford from Jefferies, set a price target of $53.00, which represents a 38.09% increase from the stock price at the time of the forecast ($38.38), and a 57.74% increase from GSK last price ($33.60).

GSK Price Target by Period

1M3M12M
# Anlaysts--3
Avg Price Target--$58.00
Last Closing Price$33.60$33.60$33.60
Upside/Downside-100.00%-100.00%72.62%

In the current month, the average price target of GSK stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to GSK's last price of $33.60. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 15, 2024Deutsche BankHoldDowngrade
Oct 31, 2024GuggenheimBuyNeutralDowngrade
Oct 07, 2024JefferiesBuyBuyHold
Oct 01, 2024BarclaysEqual-WeightEqual-WeightHold
Aug 12, 2024JefferiesBuyBuyHold
Aug 12, 2024Wells FargoEqual-WeightEqual-WeightHold
Jul 22, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Jul 11, 2024GuggenheimBuyBuyHold
Jul 08, 2024UBSNeutralDowngrade
Jul 02, 2024JefferiesBuyBuyHold
Jun 04, 2024JefferiesBuyBuyHold
May 30, 2024Goldman SachsNeutralInitialise
Sep 18, 2023William BlairOutperformOutperformHold
Feb 23, 2023SVB LeerinkMarket PerformUpgrade
Feb 23, 2023BarclaysEqual-WeightUpgrade
Jul 22, 2022CitigroupBuyInitialise

GSK's last stock rating was published by Deutsche Bank on Nov 15, 2024. The company Downgrade its GSK rating from "null" to "Hold".

GSK Financial Forecast

GSK Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
Revenue-----------$6.95B$7.38B$7.83B$6.93B$9.78B$9.53B$9.08B$8.09B$7.42B$8.74B$8.65B$7.62B$9.09B$8.90B$9.38B$7.81B$7.66B
Avg Forecast$10.22B$10.41B$10.10B$9.57B$9.90B$10.52B$9.57B$8.89B$9.66B$9.37B$8.78B$8.07B$8.90B$8.31B$7.88B$11.75B$12.87B$11.90B$10.45B$10.85B$11.88B$11.45B$9.71B$10.86B$11.78B$11.41B$9.55B$9.83B
High Forecast$10.38B$10.57B$10.26B$9.70B$10.18B$10.68B$9.72B$9.03B$9.70B$9.52B$8.92B$8.19B$9.04B$8.31B$7.88B$11.75B$12.87B$11.90B$10.45B$10.85B$11.88B$11.45B$9.71B$10.86B$11.78B$11.41B$9.55B$9.83B
Low Forecast$9.96B$10.14B$9.84B$9.45B$9.69B$10.24B$9.32B$8.66B$9.62B$9.23B$8.56B$7.86B$8.67B$8.31B$7.88B$11.75B$12.87B$11.90B$10.45B$10.85B$11.88B$11.45B$9.71B$10.86B$11.78B$11.41B$9.55B$9.83B
# Analysts1111422232111111111111111111
Surprise %-----------0.86%0.83%0.94%0.88%0.83%0.74%0.76%0.77%0.68%0.74%0.76%0.79%0.84%0.76%0.82%0.82%0.78%

GSK's average Quarter revenue forecast for Jun 23 based on 1 analysts is $8.78B, with a low forecast of $8.56B, and a high forecast of $8.92B. GSK's average Quarter revenue forecast represents a 26.36% increase compared to the company's last Quarter revenue of $6.95B (Mar 23).

GSK EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111422232111111111111111111
EBITDA-----------$2.75B$1.90B$2.17B$1.73B$3.51B$1.74B$2.93B$2.36B$2.08B$3.71B$2.51B$2.87B$2.26B$1.20B$2.71B$2.28B$2.70B
Avg Forecast$2.73B$2.79B$2.70B$2.56B$2.65B$2.81B$2.56B$2.38B$2.58B$2.51B$2.35B$2.16B$2.38B$2.35B$1.47B$3.32B$3.64B$3.36B$2.95B$3.07B$3.36B$3.23B$2.74B$3.07B$3.33B$3.22B$2.70B$2.78B
High Forecast$2.78B$2.83B$2.74B$2.59B$2.72B$2.86B$2.60B$2.41B$2.59B$2.55B$2.38B$2.19B$2.42B$2.35B$1.77B$3.32B$3.64B$3.36B$2.95B$3.07B$3.36B$3.23B$2.74B$3.07B$3.33B$3.22B$2.70B$2.78B
Low Forecast$2.66B$2.71B$2.63B$2.53B$2.59B$2.74B$2.49B$2.32B$2.57B$2.47B$2.29B$2.10B$2.32B$2.35B$1.18B$3.32B$3.64B$3.36B$2.95B$3.07B$3.36B$3.23B$2.74B$3.07B$3.33B$3.22B$2.70B$2.78B
Surprise %-----------1.27%0.80%0.92%1.17%1.06%0.48%0.87%0.80%0.68%1.10%0.78%1.05%0.74%0.36%0.84%0.84%0.97%

1 analysts predict GSK's average Quarter EBITDA for Jun 23 to be $2.35B, with a high of $2.38B and a low of $2.29B. This is -14.55% lower than GSK's previous annual EBITDA (Mar 23) of $2.75B.

GSK Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111422232111111111111111111
Net Income-----------$1.49B$1.50B$779.00M$838.00M$1.80B$930.00M$1.17B$1.40B$1.07B$677.00M$1.24B$2.26B$1.56B$1.30B$1.55B$964.00M$830.00M
Avg Forecast$911.98M$2.13B$1.84B$1.84B$785.18M$1.76B$1.58B$1.50B$1.19B$1.87B$1.44B$1.37B$907.07M$3.35B$677.29M$2.48B$2.03B$2.42B$1.63B$1.78B$1.94B$2.55B$1.66B$2.64B$2.14B$2.81B$2.08B$2.14B
High Forecast$930.04M$2.17B$1.88B$1.88B$916.04M$1.80B$1.58B$1.50B$1.25B$1.90B$1.47B$1.39B$925.02M$3.35B$812.75M$2.48B$2.03B$2.42B$1.63B$1.78B$1.94B$2.55B$1.66B$2.64B$2.14B$2.81B$2.08B$2.14B
Low Forecast$881.30M$2.06B$1.78B$1.82B$712.47M$1.71B$1.58B$1.50B$1.11B$1.80B$1.39B$1.32B$876.55M$3.35B$541.83M$2.48B$2.03B$2.42B$1.63B$1.78B$1.94B$2.55B$1.66B$2.64B$2.14B$2.81B$2.08B$2.14B
Surprise %-----------1.09%1.65%0.23%1.24%0.73%0.46%0.48%0.85%0.60%0.35%0.49%1.36%0.59%0.61%0.55%0.46%0.39%

GSK's average Quarter net income forecast for Jun 23 is $1.44B, with a range of $1.39B to $1.47B. GSK's average Quarter net income forecast represents a -3.45% decrease compared to the company's last Quarter net income of $1.49B (Mar 23).

GSK SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111422232111111111111111111
SG&A-----------$2.14B$2.44B$2.06B$2.07B$2.84B$3.26B$2.65B$2.64B$2.43B$3.16B$2.67B$2.71B$2.92B$3.44B$2.89B$2.59B$2.48B
Avg Forecast$3.25B$3.31B$3.21B$3.04B$3.15B$3.35B$3.04B$2.83B$3.07B$2.98B$2.79B$2.57B$2.83B$2.62B$1.67B$3.71B$4.06B$3.76B$3.30B$3.43B$3.75B$3.61B$3.06B$3.43B$3.72B$3.60B$3.01B$3.10B
High Forecast$3.30B$3.36B$3.26B$3.08B$3.24B$3.40B$3.09B$2.87B$3.09B$3.03B$2.84B$2.61B$2.87B$2.62B$2.00B$3.71B$4.06B$3.76B$3.30B$3.43B$3.75B$3.61B$3.06B$3.43B$3.72B$3.60B$3.01B$3.10B
Low Forecast$3.17B$3.23B$3.13B$3.01B$3.08B$3.26B$2.97B$2.76B$3.06B$2.94B$2.72B$2.50B$2.76B$2.62B$1.34B$3.71B$4.06B$3.76B$3.30B$3.43B$3.75B$3.61B$3.06B$3.43B$3.72B$3.60B$3.01B$3.10B
Surprise %-----------0.83%0.86%0.78%1.24%0.77%0.80%0.70%0.80%0.71%0.84%0.74%0.88%0.85%0.93%0.80%0.86%0.80%

GSK's average Quarter SG&A projection for Jun 23 is $2.79B, based on 1 Wall Street analysts, with a range of $2.72B to $2.84B. The forecast indicates a 30.37% rise compared to GSK last annual SG&A of $2.14B (Mar 23).

GSK EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111422232111111111111111111
EPS-----------$0.74$0.74$0.39$0.42$0.90$0.46$0.58$0.70$0.54$0.34$0.63$1.14$0.79$0.66$0.79$0.49$0.42
Avg Forecast$0.45$1.04$0.90$0.90$0.38$0.86$0.77$0.73$0.58$0.92$0.71$0.67$0.44$0.81$0.53$0.60$0.49$0.59$0.40$0.43$0.47$0.62$0.40$0.64$0.52$0.68$0.50$0.52
High Forecast$0.46$1.06$0.92$0.92$0.45$0.88$0.77$0.73$0.61$0.93$0.72$0.68$0.45$0.81$0.53$0.60$0.49$0.59$0.40$0.43$0.47$0.62$0.40$0.64$0.52$0.68$0.50$0.52
Low Forecast$0.43$1.01$0.87$0.89$0.35$0.84$0.77$0.73$0.54$0.88$0.68$0.65$0.43$0.81$0.53$0.60$0.49$0.59$0.40$0.43$0.47$0.62$0.40$0.64$0.52$0.68$0.50$0.52
Surprise %-----------1.11%1.66%0.48%0.80%1.50%0.93%0.99%1.77%1.25%0.72%1.02%2.83%1.23%1.27%1.16%0.97%0.81%

According to 1 Wall Street analysts, GSK's projected average Quarter EPS for Jun 23 is $0.71, with a low estimate of $0.68 and a high estimate of $0.72. This represents a -4.71% decrease compared to GSK previous annual EPS of $0.74 (Mar 23).

GSK Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BIIBBiogen$150.64$251.8267.17%Buy
GSKGSK$34.23$53.0054.83%Hold
MRKMerck$100.06$135.8335.75%Buy
AZNAstraZeneca$67.18$88.0030.99%Buy
AMGNAmgen$265.95$338.2227.17%Buy
SNYSanofi$48.94$62.0026.69%Buy
NVSNovartis$99.10$120.5021.59%Hold
ABBVAbbVie$175.38$211.2020.42%Buy
JNJJohnson & Johnson$146.41$175.1319.62%Buy
GILDGilead Sciences$92.80$87.30-5.93%Buy
BMYBristol-Myers Squibb Company$57.65$50.50-12.40%Hold

GSK Forecast FAQ

Is GSK a good buy?

No, according to 11 Wall Street analysts, GSK (GSK) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 27.27% of GSK's total ratings.

What is GSK's price target?

GSK (GSK) average price target is $53 with a range of $53 to $53, implying a 57.74% from its last price of $33.6. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will GSK stock go up soon?

According to Wall Street analysts' prediction for GSK stock, the company can go up by 57.74% (from the last price of $33.6 to the average price target of $53), up by 57.74% based on the highest stock price target, and up by 57.74% based on the lowest stock price target.

Can GSK stock reach $50?

GSK's average twelve months analyst stock price target of $53 supports the claim that GSK can reach $50 in the near future.

What are GSK's analysts' financial forecasts?

GSK's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $38.88B (high $39.6B, low $37.92B), average EBITDA is $10.4B (high $10.59B, low $10.14B), average net income is $5.61B (high $5.79B, low $5.5B), average SG&A $12.37B (high $12.6B, low $12.06B), and average EPS is $2.75 (high $2.84, low $2.69). GSK's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $40.31B (high $40.9B, low $39.39B), average EBITDA is $10.78B (high $10.94B, low $10.54B), average net income is $6.72B (high $6.85B, low $6.54B), average SG&A $12.82B (high $13.01B, low $12.53B), and average EPS is $3.29 (high $3.36, low $3.21).

Did the GSK's actual financial results beat the analysts' financial forecasts?

Based on GSK's last annual report (Dec 2022), the company's revenue was $29.32B, which missed the average analysts forecast of $36.85B by -20.42%. Apple's EBITDA was $8.8B, missing the average prediction of $9.52B by -7.54%. The company's net income was $4.92B, missing the average estimation of $7.41B by -33.61%. Apple's SG&A was $8.37B, missing the average forecast of $10.83B by -22.72%. Lastly, the company's EPS was $2.44, beating the average prediction of $2.38 by 2.35%. In terms of the last quarterly report (Mar 2023), GSK's revenue was $6.95B, missing the average analysts' forecast of $8.07B by -13.86%. The company's EBITDA was $2.75B, beating the average prediction of $2.16B by 27.39%. GSK's net income was $1.49B, beating the average estimation of $1.37B by 9.07%. The company's SG&A was $2.14B, missing the average forecast of $2.57B by -16.51%. Lastly, the company's EPS was $0.74, beating the average prediction of $0.67 by 10.50%